Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Melphalan

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT04812470Phase 1Completed

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases

Showing all 1 trials

Research Network

Common Treatments

  • Melphalan1
  • Autologous Tumor Infiltrating Lymphocytes1
  • Interleukin21

Active Sponsors

  • Miltenyi Biomedicine GmbH1
  • Vastra Gotaland Region1

Top Investigators

  • Lars Ny1

    Department of Oncology, Sahlgrenska University Hospital, Sweden

Related Conditions

  • Metastatic Cutaneous Melanoma1
  • Metastases To Liver1
  • Skin Melanomas1
  • Uveal Melanoma With Liver Metastases1
  • Metastatic Uveal Melanoma1

Activity Timeline